 |
264 Diseases |  |
12 Trials |
|
12 Trials |  |
579 News |  |
| «12345678» |
- || Zarnestra (tipifarnib) / Kura Oncology
Trial primary completion date, IO biomarker: Tipifarnib in Subjects With Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 12, 2017
P2, N=58, Recruiting, Sponsor: Kura Oncology, Inc.
Trial primary completion date: Sep 2017 --> Feb 2018
- | ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Journal: Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. (Pubmed Central) - Sep 16, 2017
In patients with active PN, PI results in more than doubling of the TTP compared with placebo. Imaging changes in symptomatic patients were not associated with changes in clinical status.
- | Biomarker, Enrollment open, BRCA Biomarker, PARP Biomarker, Metastases: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (clinicaltrials.gov) - Jul 28, 2017
P2, N=1500, Recruiting, Sponsor: National Cancer Institute (NCI)
Imaging changes in symptomatic patients were not associated with changes in clinical status. Not yet recruiting --> Recruiting
- | Biomarker, BRCA Biomarker, PARP Biomarker, Metastases: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (clinicaltrials.gov) - Jul 19, 2017
P2, N=1500, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=568 --> 1500
- Zarnestra (tipifarnib) / Kura Oncology
Trial primary completion date, Metastases: KO-TIP-001: Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations (clinicaltrials.gov) - May 16, 2017
P2, N=36, Recruiting, Sponsor: Kura Oncology, Inc.
N=568 --> 1500 Trial primary completion date: Mar 2017 --> Sep 2017
- | Biomarker, New P2 trial, BRCA Biomarker, PARP Biomarker, Metastases: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (clinicaltrials.gov) - May 15, 2017
P2, N=568, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Enrollment change, Trial primary completion date: Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders (clinicaltrials.gov) - May 9, 2017
P1/2, N=31, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2017 --> Sep 2017 Active, not recruiting --> Completed | N=25 --> 31 | Trial primary completion date: Dec 2016 --> Mar 2017
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Enrollment change, Metastases: Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer (clinicaltrials.gov) - Apr 27, 2017
P1, N=74, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=25 --> 31 | Trial primary completion date: Dec 2016 --> Mar 2017 Active, not recruiting --> Completed | N=56 --> 74
- | Zarnestra (tipifarnib) / Kura Oncology
Trial primary completion date: Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia (clinicaltrials.gov) - Apr 7, 2017
P2, N=25, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=56 --> 74 Trial primary completion date: Apr 2009 --> May 2007
- | Zarnestra (tipifarnib) / Kura Oncology
Enrollment open, Trial primary completion date, Metastases: Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma (clinicaltrials.gov) - Feb 23, 2017
P2, N=18, Recruiting, Sponsor: Samsung Medical Center
Trial primary completion date: Apr 2009 --> May 2007 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2016 --> Sep 2017
- |||| Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer (clinicaltrials.gov) - Feb 6, 2017
P2, N=121, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2016 --> Sep 2017 Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy: Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Dec 29, 2016
P1/2, N=31, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=80 --> 31
- | Zarnestra (tipifarnib) / Kura Oncology
Enrollment open, Trial initiation date: Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 25, 2016
P2, N=20, Recruiting, Sponsor: Kura Oncology, Inc.
N=80 --> 31 Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Oct 2016
- ||||||| Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Sep 14, 2016
P3, N=457, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Oct 2016 No longer recruiting --> Completed
- |||| Zarnestra (tipifarnib) / Kura Oncology
Enrollment open, IO biomarker: Tipifarnib in Subjects With Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 23, 2016
P2, N=58, Recruiting, Sponsor: Kura Oncology, Inc.
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- | Zarnestra (tipifarnib) / Kura Oncology
New P2 trial: Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 21, 2016
P2, N=20, Not yet recruiting, Sponsor: Kura Oncology, Inc.
- Zarnestra (tipifarnib) / Kura Oncology
Trial primary completion date, Metastases: Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer (clinicaltrials.gov) - Jun 15, 2016
P1, N=56, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Mar 2017
- ||||| Zarnestra (tipifarnib) / Kura Oncology
New P2 trial, IO biomarker: Tipifarnib in Subjects With Myelodysplastic Syndromes (clinicaltrials.gov) - May 20, 2016
P2, N=58, Not yet recruiting, Sponsor: Kura Oncology, Inc.
- |||| Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Feb 27, 2016
P2, N=82, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Trial primary completion date: Dec 2015 --> Mar 2017 No longer recruiting --> Completed
- |||| Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older (clinicaltrials.gov) - Feb 27, 2016
P2, N=88, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 27, 2016
P3, N=688, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Enrollment open: Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy (clinicaltrials.gov) - Feb 11, 2016
P2, N=30, Recruiting, Sponsor: Kura Oncology, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Zarnestra (tipifarnib) / Kura Oncology
Trial initiation date: Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy (clinicaltrials.gov) - Oct 6, 2015
P2, N=30, Not yet recruiting, Sponsor: Kura Oncology, Inc.
Not yet recruiting --> Recruiting Initiation date: Jun 2015 --> Oct 2015
- Zarnestra (tipifarnib) / Kura Oncology
New P2 trial, Metastases: Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma (clinicaltrials.gov) - Aug 28, 2015
P2, N=18, Not yet recruiting, Sponsor: Samsung Medical Center
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment change: Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2015 --> Oct 2015 N=45 --> 33
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 9, 2015
P1, N=24, Completed, Sponsor: University Health Network, Toronto
N=45 --> 33 Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Patients With Recurrent Bladder Cancer (clinicaltrials.gov) - Aug 9, 2015
P2, N=0, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed No longer recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
New P2 trial: Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy (clinicaltrials.gov) - Jun 6, 2015
P2, N=30, Not yet recruiting, Sponsor: Kura Oncology, Inc.
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment open, Metastases: KO-TIP-001: Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations (clinicaltrials.gov) - Jun 6, 2015
P2, N=36, Recruiting, Sponsor: Kura Oncology, Inc.
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer (clinicaltrials.gov) - May 22, 2015
P1/2, N=60, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Trial primary completion date, Metastases: Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer (clinicaltrials.gov) - May 4, 2015
P1/2, N=53, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jun 2010 --> Feb 2006
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer (clinicaltrials.gov) - May 2, 2015
P1/2, N=53, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2010 --> Feb 2006 Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Apr 15, 2015
P1, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 9, 2015
P2, N=21, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
New P2 trial, Metastases: KO-TIP-001: Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations (clinicaltrials.gov) - Mar 10, 2015
P2, N=36, Not yet recruiting, Sponsor: Kura Oncology, Inc.
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Enrollment change: Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 10, 2015
P1, N=12, Completed, Sponsor: Emory University
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=35 --> 12
- Zarnestra (tipifarnib) / Kura Oncology
Trial primary completion date, Metastases: Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer (clinicaltrials.gov) - Feb 27, 2015
P1, N=56, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=35 --> 12 Trial primary completion date: Dec 2014 --> Dec 2015
- Zarnestra (tipifarnib) / Kura Oncology
Trial primary completion date, Combination therapy, Metastases: Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer (clinicaltrials.gov) - Jan 13, 2015
P1/2, N=31, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Jan 2010 --> Oct 2007
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Dec 24, 2014
P1, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2010 --> Oct 2007 Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Enrollment change: Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 24, 2014
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=35 --> 20
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Trial primary completion date, Combination therapy, Metastases: Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=31, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=35 --> 20 Active, not recruiting --> Completed | Trial primary completion date: Oct 2007 --> Jan 2010
- Zarnestra (tipifarnib) / Kura Oncology
Trial primary completion date: Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission (clinicaltrials.gov) - Dec 6, 2014
P3, N=139, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Oct 2007 --> Jan 2010 Trial primary completion date: Aug 2014 --> Dec 2014
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer (clinicaltrials.gov) - Nov 18, 2014
P1/2, N=31, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2014 --> Dec 2014 N=45 --> 31 | Trial primary completion date: Dec 2014 --> Oct 2007
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial primary completion date: Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults (clinicaltrials.gov) - Sep 5, 2014
P2, N=90, Recruiting, Sponsor: National Cancer Institute (NCI)
N=45 --> 31 | Trial primary completion date: Dec 2014 --> Oct 2007 Trial primary completion date: Mar 2015 --> Jan 2016
- Zarnestra (tipifarnib) / Kura Oncology
New P1 trial: Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Aug 28, 2014
P1, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- Zarnestra (tipifarnib) / Kura Oncology
New P1/2 trial: Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders (clinicaltrials.gov) - Aug 7, 2014
P1/2, N=25, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- Zarnestra (tipifarnib) / Kura Oncology
Trial primary completion date: Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 19, 2014
P2, N=35, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2015 --> Jan 2016 Trial primary completion date: Jun 2014 --> Dec 2014
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia (clinicaltrials.gov) - May 25, 2014
P1/2, N=95, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Dec 2014 Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology, Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy: Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - May 20, 2014
P1/2, N=80, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy: Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - May 20, 2014
P1/2, N=183, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=90 --> 183